A Cancer Detection Test Fails in Major Study

New York Times - WorldCenter-LeftEN 3 min read 100% complete by Rebecca RobbinsFebruary 20, 2026 at 03:25 PM

AI Summary

medium article 3 min

A major clinical trial in Britain evaluating Grail's Galleri blood test for early cancer detection failed to demonstrate a reduction in late-stage cancers. The Galleri test, which has been sold in the U.S. since 2021 for $949, screens for cancer DNA in the blood to detect over 50 types of cancer. The study, conducted in partnership with the National Health Service of Britain, involved 142,000 healthy adults aged 50-77 who were followed for three years. Participants had their blood drawn three times, and those who tested positive via Galleri were referred for medical care. The results cast doubt on the effectiveness of blood tests for early cancer detection, despite significant investment and hope in the field.

Keywords

cancer detection 100% blood test 90% galleri test 90% grail 80% early detection 80% clinical trial 70% late-stage cancer 60% cancer dna 50% medicare 40%

Sentiment Analysis

Negative
Score: -0.40

Source Transparency

Source
New York Times - World
Political Lean
Center-Left (-0.30)
Far LeftCenterFar Right
Classification Confidence
90%
Geographic Perspective
Britain

This article was automatically classified using rule-based analysis. The political bias score ranges from -1 (far left) to +1 (far right).

Topic Connections

Explore how the topics in this article connect to other news stories

Network visualization showing 9 related topics
View Full Graph
Explore Full Topic Graph

Find Similar Articles

AI-Powered

Discover articles with similar content using semantic similarity analysis.